TABLE 1.
Patient Characteristics
| Total (n = 226) | Cases (n = 61) | Controls (n = 165) | |
|---|---|---|---|
| Median age in years (Q1–Q3) | 71 (67–76) | 72 (67.5–77) | 71 (65–75) |
| Male (frequency) | 212 (93.8%) | 62 (98.4%) | 150 (92.0%) |
| Radiotracers (frequency) | |||
| 18F-Fluorocholine | 120 (53.1%) | 51 (83.6%) | 69 (41.8%) |
| 68Ga-PSMA-11 | 79 (35.0%) | 10 (16.4%) | 69 (41.8%) |
| 18F-FDOPA | 6 (2.7%) | 0 (0%) | 6 (3.6%) |
| 68Ga-DOTATOC | 21 (9.2%) | 0 (0%) | 21 (12.8%) |
| Vaccines (frequency) | |||
| BNT162b2mRNA (Pfizer-BioNTech) | 152 (67.3%) | 46 (75.4%) | 106 (64.2%) |
| ChAdOx1-S (AstraZeneca) | 60 (26.5%) | 12 (19.7%) | 48 (29.1%) |
| mRNA-1273 (Moderna) | 11 (4.9%) | 2 (3.3%) | 9 (5.5%) |
| Ad26.COV2.S (Janssen) | 3 (1.3%) | 1 (1.6%) | 2 (1.2%) |
| Fully vaccinated (frequency) | 124 (54.9%) | 30 (49.2%) | 94 (57%) |
| Median interval between last dose and PET/CT in days (Q1–Q3) | 26 (14–51) | 15 (7–28) | 32 (18–60) |
Cases: patients with positive vaccine-related axillary or supraclavicular LNs.
Controls: patients with no vaccine-related LNs.